Montelukast

Montelukast Sodium Tablets (5mg, 10mg) is an oral selective and competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist on the WHO Model List of Essential Medicines. It blocks the binding of LTD4 (and LTC4/LTE4) to CysLT1 receptors on airway smooth muscle cells, bronchial mucosal endothelial cells, and eosinophils, inhibiting leukotriene-mediated bronchoconstriction, mucous hypersecretion, vascular permeability, and eosinophil migration. Indicated for prophylaxis and chronic treatment of bronchial asthma in adults and pediatric patients >=6 months, prevention of exercise-induced bronchoconstriction, and relief of symptoms of allergic rhinitis.

Montelukast Sodium Tablets (5mg, 10mg) is an oral selective and competitive cysteinyl leukotriene receptor-1 (CysLT1) antagonist on the WHO Model List of Essential Medicines. It blocks the binding of LTD4 (and LTC4/LTE4) to CysLT1 receptors on airway smooth muscle cells, bronchial mucosal endothelial cells, and eosinophils, inhibiting leukotriene-mediated bronchoconstriction, mucous hypersecretion, vascular permeability, and eosinophil migration. Indicated for prophylaxis and chronic treatment of bronchial asthma in adults and pediatric patients >=6 months, prevention of exercise-induced bronchoconstriction, and relief of symptoms of allergic rhinitis.

Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.

Montelukast Sodium (10mg) and Fexofenadine Hydrochloride (120mg Tablets, Suspension) is a non-sedating dual antiallergic combination. Fexofenadine is a pure second-generation H1-receptor antagonist that does not cross the blood-brain barrier (completely non-sedating), while montelukast blocks cysteinyl leukotriene CysLT1 receptors. Indicated for relief of symptoms associated with allergic rhinitis (sneezing, runny nose, itchy/watery eyes, nasal congestion) in patients needing daytime alertness.

Acebrophylline Capsules / Tablets (100mg, 200mg Sustained Release; alone or with Montelukast 10mg or Acetylcysteine 600mg) is a fixed salt of ambroxol and theophylline-7-acetic acid on the PMBI formulary. It exerts a triple therapeutic action: potent bronchodilation via phosphodiesterase inhibition; mucoregulatory and surfactant-stimulating action via ambroxol (stimulating alveolar type II pneumocytes to produce pulmonary surfactant, reducing mucus viscosity and improving mucociliary clearance); and anti-inflammatory inhibition of phospholipase A2 and leukotriene C4. Indicated for bronchial asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and chronic spastic bronchitis with thick viscid sputum.

Desloratadine (5mg) and Montelukast (10mg Tablets) combines the active descarboethoxyl metabolite of loratadine with a CysLT1 leukotriene antagonist. Indicated for allergic rhinitis and allergic asthma.

Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.

Doxofylline Tablets (400mg; alone or with Montelukast 10mg) is a novel xanthine derivative bronchodilator on the PMBI formulary. Unlike theophylline, it contains a dioxolane group at position 7 that specifically inhibits phosphodiesterase without binding to adenosine receptors or interfering with calcium influx. This confers potent bronchodilatory and anti-inflammatory activity with dramatically fewer cardiac, gastric, and CNS side effects (negligible tachycardia, insomnia, or gastric hypersecretion) and a 10-fold wider therapeutic window. Indicated for maintenance treatment of bronchial asthma, COPD, and spastic bronchitis.

Bilastine (10mg/20mg) and Montelukast (4mg/10mg Tablets, Orodispersible Tablets) is a modern, non-sedating antiallergic combination. Bilastine is a highly selective second-generation H1-antihistamine with zero anticholinergic activity and no blood-brain barrier penetration; montelukast blocks cysteinyl leukotrienes. Indicated for allergic rhinitis and chronic urticaria.

Bilastine (10mg/20mg) and Montelukast (4mg/10mg Tablets, Orodispersible Tablets) is a modern, non-sedating antiallergic combination. Bilastine is a highly selective second-generation H1-antihistamine with zero anticholinergic activity and no blood-brain barrier penetration; montelukast blocks cysteinyl leukotrienes. Indicated for allergic rhinitis and chronic urticaria.

Montelukast Sodium (4mg/10mg) and Levocetirizine Dihydrochloride (2.5mg/5mg Tablets, Syrup, with or without Ambroxol SR 75mg) is a premier dual-action antiallergic and anti-inflammatory combination on the WHO Model List framework. Montelukast is a selective cysteinyl leukotriene receptor-1 (CysLT1) antagonist that blocks the bronchoconstricting, mucus-secreting, and eosinophil-recruiting actions of LTD4. Levocetirizine is an active R-enantiomer second-generation H1-antihistamine that blocks histamine-mediated itching, sneezing, and vascular permeability. Together, they simultaneously block both early-phase (histamine) and late-phase (leukotriene) allergic inflammatory cascades. Indicated for seasonal and perennial allergic rhinitis, allergic rhinitis with co-existing asthma, and chronic urticaria.

Montelukast (10mg) and Ebastine (10mg Tablets) combines a long-acting second-generation H1-blocker (prodrug of carebastine) with a CysLT1 leukotriene receptor antagonist. Provides sustained 24-hour symptom relief in allergic rhinitis and chronic idiopathic urticaria.

Montelukast Sodium (10mg) and Fexofenadine Hydrochloride (120mg Tablets, Suspension) is a non-sedating dual antiallergic combination. Fexofenadine is a pure second-generation H1-receptor antagonist that does not cross the blood-brain barrier (completely non-sedating), while montelukast blocks cysteinyl leukotriene CysLT1 receptors. Indicated for relief of symptoms associated with allergic rhinitis (sneezing, runny nose, itchy/watery eyes, nasal congestion) in patients needing daytime alertness.

Rupatadine (10mg) and Montelukast (10mg Tablets) is a dual H1-receptor and Platelet-Activating Factor (PAF) antagonist combined with a leukotriene antagonist. Simultaneously blocks three distinct allergic mediators (histamine, PAF, and LTD4), delivering powerful relief in severe allergic rhinitis and urticaria.